Trial ID or NCT#

NCT01151761

Status

not recruiting iconNOT RECRUITING

Purpose

The purpose of this study is to determine progression-free survival at 12 months for stereotactic body radiotherapy (SBRT) and chemotherapy for unresectable hilar cholangiocarcinoma (CCA).

Official Title

Phase II Study of Stereotactic Body Radiotherapy (SBRT) and Chemotherapy for Unresectable Cholangiocarcinoma Followed by Liver Transplantation

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

C. Andrew Bonham
C. Andrew Bonham
Transplant surgeon, Liver transplant surgeon, Kidney transplant surgeon, Hepatobiliary surgeon
Associate Professor of Surgery (Abdominal Transplantation)
George A. Fisher Jr.
George A. Fisher Jr.
Medical oncologist, Gastrointestinal specialist
Colleen Haas Chair in the School of Medicine
Aijaz Ahmed, MD
Aijaz Ahmed, MD
Hepatologist, Transplant hepatologist
Professor of Medicine (Gastroenterology and Hepatology)
Daniel Chang
Daniel Chang
Radiation oncologist
Sue and Bob McCollum Professor

Contact us to find out if this trial is right for you.

CONTACT

Ccto-office@stanford.edu
(650) 498-7061